Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study

Abstract Elevated concentrations of acylcarnitines have been associated with higher risk of obesity, type 2 diabetes and cardiovascular disease. The aim of the present study was to assess the association between L-carnitine and acylcarnitine profiles, and 2-year risk of incident lower-extremity func...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Francisco Félix Caballero, Ellen A. Struijk, Alberto Lana, Antonio Buño, Fernando Rodríguez-Artalejo, Esther Lopez-Garcia
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b1771727ad0e481588e5a7ab1ae2f31f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1771727ad0e481588e5a7ab1ae2f31f
record_format	dspace
spelling	oai:doaj.org-article:b1771727ad0e481588e5a7ab1ae2f31f2021-12-02T12:09:26ZPlasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study10.1038/s41598-021-82912-y2045-2322https://doaj.org/article/b1771727ad0e481588e5a7ab1ae2f31f2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82912-yhttps://doaj.org/toc/2045-2322Abstract Elevated concentrations of acylcarnitines have been associated with higher risk of obesity, type 2 diabetes and cardiovascular disease. The aim of the present study was to assess the association between L-carnitine and acylcarnitine profiles, and 2-year risk of incident lower-extremity functional impairment (LEFI). This case–control study is nested in the Seniors-ENRICA cohort of community-dwelling older adults, which included 43 incident cases of LEFI and 86 age- and sex- matched controls. LEFI was assessed with the Short Physical Performance Battery. Plasma L-carnitine and 28 acylcarnitine species were measured. After adjusting for potential confounders, medium-chain acylcarnitines levels were associated with 2-year incidence of LEFI [odds ratio per 1-SD increase: 1.69; 95% confidence interval: 1.08, 2.64; p = 0.02]. Similar results were observed for long-chain acylcarnitines [odds ratio per 1-SD increase: 1.70; 95% confidence interval: 1.03, 2.80; p = 0.04]. Stratified analyses showed a stronger association between medium- and long-chain acylcarnitines and incidence of LEFI among those with body mass index and energy intake below the median value. In conclusion, higher plasma concentrations of medium- and long-chain acylcarnitines were associated with higher risk of LEFI. Given the role of these molecules on mitochondrial transport of fatty acids, our results suggest that bioenergetics dysbalance contributes to LEFI.Francisco Félix CaballeroEllen A. StruijkAlberto LanaAntonio BuñoFernando Rodríguez-ArtalejoEsther Lopez-GarciaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Francisco Félix Caballero Ellen A. Struijk Alberto Lana Antonio Buño Fernando Rodríguez-Artalejo Esther Lopez-Garcia Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study
description	Abstract Elevated concentrations of acylcarnitines have been associated with higher risk of obesity, type 2 diabetes and cardiovascular disease. The aim of the present study was to assess the association between L-carnitine and acylcarnitine profiles, and 2-year risk of incident lower-extremity functional impairment (LEFI). This case–control study is nested in the Seniors-ENRICA cohort of community-dwelling older adults, which included 43 incident cases of LEFI and 86 age- and sex- matched controls. LEFI was assessed with the Short Physical Performance Battery. Plasma L-carnitine and 28 acylcarnitine species were measured. After adjusting for potential confounders, medium-chain acylcarnitines levels were associated with 2-year incidence of LEFI [odds ratio per 1-SD increase: 1.69; 95% confidence interval: 1.08, 2.64; p = 0.02]. Similar results were observed for long-chain acylcarnitines [odds ratio per 1-SD increase: 1.70; 95% confidence interval: 1.03, 2.80; p = 0.04]. Stratified analyses showed a stronger association between medium- and long-chain acylcarnitines and incidence of LEFI among those with body mass index and energy intake below the median value. In conclusion, higher plasma concentrations of medium- and long-chain acylcarnitines were associated with higher risk of LEFI. Given the role of these molecules on mitochondrial transport of fatty acids, our results suggest that bioenergetics dysbalance contributes to LEFI.
format	article
author	Francisco Félix Caballero Ellen A. Struijk Alberto Lana Antonio Buño Fernando Rodríguez-Artalejo Esther Lopez-Garcia
author_facet	Francisco Félix Caballero Ellen A. Struijk Alberto Lana Antonio Buño Fernando Rodríguez-Artalejo Esther Lopez-Garcia
author_sort	Francisco Félix Caballero
title	Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study
title_short	Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study
title_full	Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study
title_fullStr	Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study
title_full_unstemmed	Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study
title_sort	plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b1771727ad0e481588e5a7ab1ae2f31f
work_keys_str_mv	AT franciscofelixcaballero plasmaacylcarnitinesandriskoflowerextremityfunctionalimpairmentinolderadultsanestedcasecontrolstudy AT ellenastruijk plasmaacylcarnitinesandriskoflowerextremityfunctionalimpairmentinolderadultsanestedcasecontrolstudy AT albertolana plasmaacylcarnitinesandriskoflowerextremityfunctionalimpairmentinolderadultsanestedcasecontrolstudy AT antoniobuno plasmaacylcarnitinesandriskoflowerextremityfunctionalimpairmentinolderadultsanestedcasecontrolstudy AT fernandorodriguezartalejo plasmaacylcarnitinesandriskoflowerextremityfunctionalimpairmentinolderadultsanestedcasecontrolstudy AT estherlopezgarcia plasmaacylcarnitinesandriskoflowerextremityfunctionalimpairmentinolderadultsanestedcasecontrolstudy
_version_	1718394650499219456

Plasma acylcarnitines and risk of lower-extremity functional impairment in older adults: a nested case–control study

Ejemplares similares